Behind the Scenes of Amgen's Latest Options Trends
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Amgen's Options: A Look at What the Big Money is Thinking
The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...
pharmaphorum3d
A history of: Amgen
Amgen’s focus on blood cell medications continued in the 2000s, with the approval of Aranesp for the treatment of anaemic patients with chronic renal failure, and the 2002 approval of Neulasta ...
Amgen Inc. (AMGN): Among the Best Undervalued Stocks to Invest In Now
Aranesp, Neulasta, and Repatha, among others. On March 4, David Amsellem, analyst at Piper Sandler, reiterated a Buy rating ...
What is William Blair’s Forecast for Amgen Q4 Earnings?
Investment analysts at William Blair issued their Q4 2026 earnings per share estimates for Amgen in a research report issued ...
Q1 Earnings Forecast for Amgen Issued By William Blair
Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Amgen in a research note issued on ...
Amgen (AMGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nasdaq8d
Amgen's Options: A Look at What the Big Money is Thinking
Deep-pocketed investors have adopted a bullish approach towards Amgen (NASDAQ:AMGN), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...